Direct-To-Consumer Teledermatology For Male Androgenetic Alopecia: Narrative Review

This study found that topical finasteride mixed with minoxidil improved hair appearance and self-esteem in men with androgenetic alopecia, but it was not superior to oral finasteride and had lower treatment adherence.

This study found that the increasing visits to online prescription platforms for MQ-based finasteride treatment in androgenetic alopecia suggest a significant shift in medical care towards digital health services.

This study found that users of a German direct-to-consumer teledermatology platform for finasteride reported improvements in hair appearance and self-esteem, though 12% experienced treatment-related adverse events.

In this study, patients using the digitally enabled platform Keeps for male pattern hair loss treatment reported positive health outcomes, with 81% experiencing hair regrowth or ceasing hair loss after six months.

This report discusses the improved access to care and patient benefits of telemedicine for men with androgenetic alopecia, but it provides no new clinical results.

This study found that topical finasteride significantly increased hair count in men with androgenetic alopecia compared to placebo while maintaining similar efficacy to oral finasteride but with lower systemic exposure and a reduced impact on serum DHT levels, potentially minimizing sexual side effects.

This guideline review by the European Dermatology Forum evaluates current treatments for androgenetic alopecia but reports no new research findings, aiming to assist dermatologists in selecting safe and effective therapies.